New Findings Show Inhibiting Powerful Protein with New Agents May Supply Broad Benefit for Lymphoma Patients A soon-to-be-tested class of drug inhibitors were predicted to help a limited number of patients with B-cell lymphomas with mutations affecting the EZH2 protein. However, a research team, led by investigators at Weill Cornell Medical College, now report that these agents may, in fact, help a much broader cross section of lymphoma patients...
More...
More...